Authors: Tobias Thornblad; Thomas Hedner
Addresses: Innovation and Entrepreneurship, The Sahlgrenska Academy, University of Gothenburg, PO Box 417, Gothenburg 405 30, Sweden. ' Innovation and Entrepreneurship, The Sahlgrenska Academy, University of Gothenburg, PO Box 417, Gothenburg 405 30, Sweden
Abstract: In the biomedical field multiple stakeholders may collaboratively develop, package and build transactions around technology. This is often referred to as open innovation, open biotechnology or open source R&D. Intellectual Property (IP) and IP rights play important roles in collaborative platforms but little research has previously assessed the impact that such platforms exert on corporate IP-strategies. A case study was therefore conducted of the Innovative Medicines Initiative (IMI), CAMBIA Biological Open Source (BiOS) and the Medicines for Malaria Venture (MMV). Our results impact managerial decision-makers at pharmaceutical, biotech and agriscience companies intending to implement corporate open innovation and IP strategies.
Keywords: intellectual property strategy; open IP platforms; open innovation; open biotechnology; open source R&D; life sciences; multiple stakeholders; research and development; biomedical; pharmaceutical companies; biotech companies; agriscience companies.
International Journal of Technology Intelligence and Planning, 2012 Vol.8 No.1, pp.60 - 74
Available online: 17 Jun 2012 *Full-text access for editors Access for subscribers Purchase this article Comment on this article